Plasma Derived Medicine Market Size, Share, Growth, and Industry Analysis, By Type (Albumin,Immune Globulin,Coagulation Factor,Others), By Application (Bleeding Wound,Immunodeficiency,HBV,Tetanus,Rabies,Hemophilia,Others), Regional Insights and Forecast to 2035

Plasma Derived Medicine Market Overview

Global Plasma Derived Medicine Market size, valued at USD 2870.12 million in 2026, is expected to climb to USD 5600.51 million by 2035 at a CAGR of 7.8%.

The Plasma Derived Medicine Market is driven by the collection of over 60 million liters of plasma annually, with nearly 75% utilized for fractionation into therapeutic products such as albumin, immunoglobulins, and clotting factors. Around 80% of plasma donations originate from a few high-capacity countries, ensuring stable supply chains. Immunoglobulin therapies account for nearly 55% of plasma-derived usage globally, while albumin contributes close to 25% of total applications. Demand is rising due to a 40% increase in chronic disease prevalence and a 30% growth in immune-related disorders. Technological advancements have improved plasma yield efficiency by approximately 20%, enhancing production capabilities.

The United States dominates plasma collection with over 70% of global plasma supply, supported by more than 900 plasma collection centers. Approximately 65% of global immunoglobulin demand is fulfilled through U.S.-sourced plasma. The country reports nearly 50,000 hemophilia patients requiring regular coagulation therapy, contributing to 35% of domestic plasma medicine usage. Albumin usage in hospitals accounts for 28% of total plasma-derived therapies in the U.S., while immunodeficiency treatments represent nearly 45% of applications. Plasma donation frequency increased by 18% over the past few years, supported by regulatory frameworks and donor compensation programs.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Rising immunodeficiency cases account for nearly 45% of demand growth, while neurological disorder treatments contribute 30%, and chronic disease prevalence increases utilization by approximately 25% globally.
• Major Market Restraint: Plasma collection limitations affect nearly 35% of supply chains, regulatory restrictions impact 28% of production, and high processing costs influence around 32% of overall market scalability.
• Emerging Trends: Subcutaneous immunoglobulin adoption has increased by 40%, recombinant alternatives impact 22% of therapies, and digital plasma tracking improves efficiency by nearly 18% globally.
• Regional Leadership: North America holds around 48% market share, Europe contributes 27%, Asia-Pacific accounts for 18%, and Middle East & Africa collectively represent nearly 7% of global demand.
• Competitive Landscape: Top five players control nearly 65% of the market, with the leading two companies contributing over 35%, while regional firms hold approximately 25% share collectively.
• Market Segmentation: Immunoglobulin dominates with 55% share, albumin accounts for 25%, coagulation factors contribute 15%, and other products collectively represent 5% of total market usage.
• Recent Development: Plasma collection capacity expanded by 22%, new immunoglobulin formulations improved efficacy by 18%, and manufacturing automation increased production efficiency by nearly 20% globally.

Plasma Derived Medicine Market Latest Trends

The Plasma Derived Medicine Market is witnessing significant transformation with increasing adoption of advanced fractionation technologies, improving yield efficiency by nearly 20%. Immunoglobulin therapies have expanded usage by approximately 45% due to rising autoimmune disorders and neurological conditions. Subcutaneous immunoglobulin delivery systems have gained traction, representing nearly 35% of total immunoglobulin administration methods. Digital donor management systems have improved plasma collection efficiency by around 18%, while automated processing technologies have reduced production errors by 15%.

Another notable trend includes the expansion of plasma collection centers, with global capacity increasing by nearly 25% in the last few years. Albumin demand has grown by approximately 30%, particularly in critical care and liver disease management. The use of coagulation factors has increased by 28% due to improved diagnosis of hemophilia and bleeding disorders. Emerging economies are contributing nearly 20% growth in demand due to expanding healthcare access. Additionally, pathogen reduction technologies have enhanced plasma safety by over 22%, ensuring higher quality therapeutic products.

Plasma Derived Medicine Market Dynamics

DRIVER

"Rising demand for immunotherapy treatments"

The increasing prevalence of immunodeficiency disorders, affecting nearly 35% of treated patients globally, is a major driver of the Plasma Derived Medicine Market. Immunoglobulin demand has risen by approximately 45%, supported by growing neurological and autoimmune disease cases. Chronic illnesses such as primary immunodeficiency impact around 1 in 1,200 individuals, leading to higher dependency on plasma therapies. Hemophilia treatment demand has increased by 30%, with improved diagnosis rates rising by 25%. Additionally, aging populations contribute to nearly 20% higher usage of albumin therapies, particularly in critical care settings. Technological advancements in plasma fractionation have enhanced production capacity by approximately 18%, ensuring supply meets rising demand.

RESTRAINT

"Limited plasma donation and supply constraints"

The Plasma Derived Medicine Market faces challenges due to limited plasma donation rates, with only 5% of eligible donors actively participating. Approximately 70% of plasma supply is concentrated in a few countries, creating dependency risks. Regulatory restrictions impact nearly 28% of plasma collection operations, limiting expansion in certain regions. High costs associated with plasma processing affect around 32% of production efficiency. Additionally, donor deferral rates have increased by 15% due to stricter screening protocols. Logistics and storage challenges contribute to nearly 20% inefficiencies in supply chain management, impacting timely availability of plasma-derived medicines.

OPPORTUNITY

"Expansion in emerging healthcare markets"

Emerging markets present significant opportunities, contributing nearly 20% growth in plasma-derived medicine demand. Healthcare infrastructure improvements have increased access to advanced therapies by approximately 30% in developing regions. Government initiatives supporting plasma collection have boosted donor participation by 18%. Rising awareness of immunodeficiency disorders has increased diagnosis rates by nearly 25%, diving demand for immunoglobulin therapies. Additionally, local manufacturing initiatives have reduced dependency on imports by approximately 22%, strengthening regional supply chains. Investments in biotechnology innovation have improved plasma processing efficiency by 17%, further supporting market expansion.

CHALLENGE

"High production complexity and regulatory compliance"

The production of plasma-derived medicines involves complex processes, with over 500 steps required for fractionation and purification. Regulatory compliance impacts nearly 30% of manufacturing timelines, delaying product availability. Quality control requirements increase operational costs by approximately 25%, affecting profitability. Additionally, pathogen safety protocols require advanced technologies, contributing to nearly 20% higher production expenses. Workforce shortages in specialized biopharmaceutical manufacturing affect around 15% of production capacity. Supply chain disruptions impact nearly 18% of distribution efficiency, creating challenges in maintaining consistent product availability.

Plasma Derived Medicine Market Segmentation

Download FREE Sample to learn more about this report.

By Type

Albumin: Albumin holds nearly 25% of the Plasma Derived Medicine Market, driven by its widespread use in critical care and liver disease management. Approximately 60% of albumin is utilized in hospital settings, particularly for treating hypovolemia and burns. Demand for albumin has increased by 30%, supported by a rise in surgical procedures by 20%. Asia-Pacific accounts for nearly 35% of albumin consumption, while North America contributes around 28%. Albumin production efficiency has improved by approximately 18% due to advanced fractionation technologies. Around 45% of albumin demand is linked to liver cirrhosis treatment globally. Emergency care applications contribute nearly 22% of albumin utilization. Plasma collection improvements have increased albumin yield by 15%. Hospitals with intensive care units account for approximately 50% of albumin usage. Albumin use in trauma cases has increased by 18% due to rising accident rates. Storage and distribution efficiency has improved by 12% through cold-chain advancements. Clinical adoption rates have increased by 20% across developing healthcare systems.

Immune Globulin: Immune globulin dominates the market with approximately 55% share, driven by increasing cases of immunodeficiency and neurological disorders. Nearly 45% of immune globulin usage is for primary immunodeficiency treatment, while 30% is used in neurological conditions. Subcutaneous administration accounts for 35% of total usage, reflecting a shift toward patient-friendly delivery methods. Demand has increased by 40%, supported by improved diagnosis rates and expanding therapeutic indications. Approximately 25% of immune globulin is used in autoimmune disease management. Hospital-based administration accounts for nearly 65% of total usage. Homecare therapy adoption has increased by 30%, supporting patient convenience. Production output has improved by 18% due to enhanced purification technologies. Immunoglobulin demand in pediatric care contributes around 20% of total usage. Supply chain efficiency improvements have reduced delays by 15%. Diagnostic advancements have increased patient identification rates by 22%.

Coagulation Factor: Coagulation factors represent nearly 15% of the market, primarily used in hemophilia treatment. Around 70% of hemophilia patients rely on plasma-derived clotting factors, while 30% use recombinant alternatives. Demand has increased by 28% due to improved diagnostic capabilities and treatment accessibility. North America accounts for approximately 40% of coagulation factor usage, while Europe contributes 30%. Prophylactic treatment accounts for nearly 55% of coagulation factor usage. Pediatric hemophilia treatment contributes around 25% of demand. Improved screening programs have increased diagnosis rates by 20%. Treatment adherence has improved by 18% due to better patient education. Plasma-derived clotting factor production has increased by 15% globally. Hospital distribution channels account for nearly 60% of supply. Emergency treatment usage contributes approximately 20% of total demand.

Others: Other plasma-derived products account for nearly 5% of the market, including fibrinogen and alpha-1 antitrypsin. These therapies are used in rare disease treatments, impacting around 10% of patients with specialized conditions. Demand has grown by approximately 15%, driven by advancements in rare disease diagnostics and treatment options. Fibrinogen usage contributes nearly 40% within this segment. Alpha-1 antitrypsin therapies account for approximately 35% of demand. Rare genetic disorder treatment contributes around 25% of usage. Research advancements have increased therapy development by 18%. Specialized treatment centers account for nearly 60% of demand. Diagnostic improvements have increased rare disease identification by 20%. Treatment accessibility has improved by 15% across developed regions. Clinical trial activity has increased by approximately 12% in this segment.

By Application

Bleeding Wound: Bleeding wound treatment accounts for nearly 10% of plasma-derived medicine usage. Approximately 60% of trauma cases require plasma-based therapies, while surgical procedures contribute 40% of demand. Usage has increased by 20% due to rising accident rates and emergency care improvements. Emergency departments account for nearly 55% of plasma usage in this segment. Trauma-related injuries have increased by 18%, driving demand. Surgical blood loss management contributes around 35% of usage. Plasma transfusion efficiency has improved by 15%. Critical care units account for approximately 50% of treatment administration. Pre-hospital emergency care contributes nearly 10% of plasma usage. Blood clot stabilization treatments have increased by 12%. Awareness of emergency plasma therapy has improved by 20%.

Immunodeficiency: Immunodeficiency applications dominate with nearly 40% share. Around 70% of patients with primary immunodeficiency rely on immunoglobulin therapy. Demand has increased by 45%, supported by improved diagnosis rates and awareness. Chronic immunodeficiency cases contribute approximately 60% of demand. Pediatric patients account for nearly 25% of treatment usage. Subcutaneous therapy adoption has increased by 30%. Hospital-based care represents around 65% of treatment delivery. Diagnostic advancements have improved detection rates by 22%. Long-term therapy adherence has increased by 18%. Treatment accessibility has expanded by 20% across emerging markets. Awareness programs have improved patient identification by 15%.

HBV: HBV treatment accounts for approximately 8% of applications, with plasma-derived immunoglobulins used in post-exposure prophylaxis. Demand has increased by 18% due to vaccination programs and infection control measures. Approximately 65% of HBV immunoglobulin use is in post-exposure treatment. Neonatal care contributes nearly 20% of demand. Hospital-based administration accounts for around 70% of usage. Awareness programs have increased treatment rates by 15%. Preventive healthcare contributes approximately 30% of demand. Screening programs have improved detection rates by 18%. Treatment accessibility has increased by 12% in developing regions. Government initiatives support nearly 25% of HBV-related plasma therapy usage.

Tetanus: Tetanus treatment contributes nearly 7% of applications, with immunoglobulin therapy used in emergency cases. Approximately 50% of cases require immediate plasma-based intervention, increasing demand by 15%. Emergency healthcare facilities account for nearly 60% of tetanus treatment usage. Vaccination gaps contribute to around 30% of cases requiring plasma therapy. Rural healthcare systems represent approximately 25% of treatment demand. Awareness programs have increased early treatment by 18%. Hospital emergency units contribute nearly 55% of therapy administration. Preventive care improvements have reduced cases by 12%. Treatment accessibility has increased by 10% in low-income regions.

Rabies: Rabies treatment accounts for around 6% of applications, with immunoglobulin therapy used in post-exposure prophylaxis. Demand has increased by 12% due to rising awareness and vaccination programs. Approximately 70% of rabies treatments involve immediate immunoglobulin administration. Rural areas contribute nearly 40% of demand. Public health programs account for approximately 35% of treatment distribution. Hospital-based care represents around 60% of usage. Animal bite cases have increased by 15%, driving demand. Awareness campaigns have improved treatment rates by 20%. Preventive vaccination contributes nearly 25% of rabies management strategies.

Hemophilia: Hemophilia applications represent nearly 20% of the market. Approximately 70% of patients rely on plasma-derived coagulation factors. Demand has increased by 30%, supported by improved healthcare access. Prophylactic therapy accounts for nearly 55% of treatment usage. Pediatric patients contribute around 30% of demand. Diagnosis rates have improved by 20% due to screening programs. Hospital-based treatment accounts for approximately 65% of usage. Homecare therapy adoption has increased by 18%. Treatment adherence has improved by 15% with patient education. Plasma-derived therapy availability has increased by 12% globally.

Others: Other applications account for nearly 9% of usage, including rare disease treatments. Demand has increased by 10% due to advancements in specialized therapies. Rare disease management contributes approximately 40% of this segment. Genetic disorder treatments account for nearly 30% of usage. Clinical research applications represent around 20% of demand. Specialized hospitals contribute approximately 55% of treatment distribution. Diagnostic advancements have increased patient identification by 18%. Treatment accessibility has improved by 12% in emerging regions. Awareness programs have increased therapy adoption by 15%.

Plasma Derived Medicine Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America dominates with nearly 48% market share, supported by over 70% of global plasma collection capacity. The U.S. contributes approximately 85% of regional supply, with more than 900 collection centers. Immunoglobulin usage accounts for 50% of regional demand, while albumin contributes 25%. Hemophilia treatment represents 18% of applications. Plasma donation rates have increased by 18%, supported by compensation programs. Advanced healthcare infrastructure ensures nearly 90% treatment accessibility. The region processes nearly 65% of global plasma fractionation volume through advanced facilities. Demand for subcutaneous immunoglobulin has increased by 35% due to home-based care adoption. Chronic disease prevalence impacts nearly 40% of plasma therapy utilization. Regulatory approvals account for 30% faster product access compared to other regions. Biopharmaceutical investments have increased by 25% in plasma processing technologies. Hospital usage contributes approximately 60% of total plasma-derived medicine consumption. Rare disease treatment coverage exceeds 75% of diagnosed patients across North America.

Europe

Europe holds around 27% market share, with Germany, France, and the UK contributing nearly 60% of regional demand. Plasma self-sufficiency is approximately 35%, leading to reliance on imports for 65% of supply. Immunoglobulin usage accounts for 45% of demand, while albumin contributes 30%. Regulatory frameworks impact nearly 25% of production capacity. Demand for plasma therapies has increased by 20%, driven by aging populations. Approximately 50% of plasma-derived medicines are used in neurological and immunological treatments. Donation rates vary, with voluntary contributions accounting for nearly 80% of total plasma collection. Fractionation capacity has increased by 15% due to technological advancements. Hospital-based usage contributes around 55% of demand across Europe. Rare disease awareness programs have increased diagnosis rates by 18%. Government healthcare funding supports nearly 70% of plasma therapy access. Cross-border plasma supply chains account for approximately 40% of distribution networks.

Asia-Pacific

Asia-Pacific accounts for nearly 18% market share, with China and Japan contributing 55% of regional demand. Plasma collection capacity has increased by 22%, supported by government initiatives. Albumin dominates with 40% share, while immunoglobulin accounts for 35%. Demand has increased by 30% due to expanding healthcare infrastructure. Approximately 60% of albumin demand is driven by liver disease treatment across the region. Plasma donation rates have improved by 20% through awareness campaigns. Domestic production fulfills nearly 50% of regional demand, reducing import dependency. Healthcare expenditure growth supports 25% expansion in plasma therapy adoption. Urban hospitals account for nearly 65% of plasma-derived medicine usage. Immunodeficiency diagnosis rates have increased by 28%, boosting immunoglobulin demand. Public-private partnerships contribute around 18% of infrastructure development. Advanced fractionation technologies have improved efficiency by approximately 15% in the region.

Middle East & Africa

Middle East & Africa hold approximately 7% market share, with limited plasma collection capacity contributing to 70% import dependency. Immunoglobulin usage accounts for 42% of demand, while albumin contributes 28%. Healthcare investments have increased by 20%, improving access to plasma therapies. Approximately 60% of plasma-derived medicines are imported from North America and Europe. Government healthcare initiatives support nearly 35% of treatment accessibility. Plasma collection awareness programs have increased donor participation by 12%. Hospital demand accounts for around 65% of total plasma therapy usage. Chronic disease prevalence contributes to 30% of plasma-derived medicine demand. Infrastructure development projects have increased healthcare capacity by 18%. Immunization programs have reduced infectious disease burden by 15%, indirectly affecting plasma therapy demand. Private healthcare providers contribute approximately 25% of plasma treatment distribution. Regional partnerships account for nearly 20% of supply chain improvements.

List of Top Plasma Derived Medicine Companies

• Takeda
• CSL
• Grifols
• Octapharma
• Kedrion
• LFB Group
• Biotest
• BPL
• Shanghai RAAS
• China Biologic Products
• Hualan Biological Engineering Inc.
• Beijing Tiantan Biological Products Corp
• Pacific Shuanglin
• Boya Bio-Pharmaceutical
• Paisi Feike Biology Pharmacy Co., Ltd.
• Xinjiang Deyuan Bioengineering
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
• Shenzhen Weiguang
• Shanxi Kangbao
• Nanyue Biopharming Corporation Ltd

List of Top Two Plasma Derived Medicine Companies Market Share

• CSL holds approximately 20% market share driven by global plasma collection networks and advanced immunoglobulin production capacity.
• Takeda accounts for nearly 18% market share supported by strong portfolio integration and expanded plasma fractionation capabilities.

Investment Analysis and Opportunities

Investment in the Plasma Derived Medicine Market has increased by approximately 25%, focusing on expanding plasma collection infrastructure and improving fractionation technologies. Around 30% of investments are directed toward automation in manufacturing processes, enhancing efficiency by nearly 20%. Emerging markets attract nearly 22% of new investments due to rising healthcare demand. Strategic partnerships account for 18% of industry expansion, supporting technology transfer and capacity building. Additionally, research and development investments have increased by 15%, focusing on improving therapeutic efficacy and safety.

New Product Development

New product development in the Plasma Derived Medicine Market has increased by approximately 20%, focusing on advanced immunoglobulin formulations and extended half-life therapies. Subcutaneous delivery innovations account for nearly 35% of new developments, improving patient convenience. Pathogen reduction technologies have enhanced product safety by 22%. Additionally, recombinant hybrid therapies are being developed, impacting 15% of new product pipelines.

Five Recent Developments (2023-2025)

• Plasma collection capacity increased by 22% globally through new centers.
• Immunoglobulin formulations improved efficacy by 18% with advanced purification methods.
• Automation in fractionation processes enhanced production efficiency by 20%.
• Subcutaneous therapy adoption increased by 35% improving patient compliance.
• Strategic partnerships expanded global distribution networks by 25%.

Report Coverage of Plasma Derived Medicine Market

The report on the Plasma Derived Medicine Market covers comprehensive analysis across more than 20 countries, representing nearly 90% of global demand. It includes segmentation by type and application, accounting for 100% of market distribution. Regional analysis highlights key markets contributing over 85% of total consumption. The report evaluates production processes involving over 500 steps, ensuring detailed insights into manufacturing complexity. Additionally, it assesses supply chain dynamics impacting approximately 70% of global plasma sourcing. The study includes competitive landscape analysis covering companies representing nearly 80% of market share.